Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal Women
Osteoporosis Postmenopausal
About this trial
This is an interventional treatment trial for Osteoporosis Postmenopausal focused on measuring Treatment osteoporosis postmenopausal
Eligibility Criteria
Inclusion Criteria: Subjects meeting all of the following criteria were considered for enrollment into the study : ·Ambulatory, healthy postmenopausal women with : Natural menopause and more than 5 years after their last menstrual period. Or surgical menopause and more than 5 years after surgery (blood hormone tests required for subjects less than 65 years of age who had uterus removed without removal of ovaries at time of surgery). Osteoporosis (lumbar spine T-score more than 2.5 SD below the mean value in normal young women or more than 2.0 SD below the mean value in normal young women and at least 1 fracture of a vertebra (thoracic-lumbar T4-L4)). Exclusion Criteria: Subjects with any of the following criteria were not considered for enrollment into the study : ·Women who have received hormone replacement therapy (with estrogen by mouth and/or progestogen and/or androgen) or raloxifene, or other bone active drugs, such as calcitonin, calcitriol/calcidiol/alfacalcidol, parathyroid hormone or any bisphosphonate within 3 months before first dose of study medication.
Sites / Locations
- Sanofi-Aventis
- Sanofi-Aventis
- Sanofi-Aventis
- Sanofi-Aventis
- Sanofi-Aventis
- Sanofi-Aventis
- Sanofi-Aventis
- Sanofi-Aventis
- Sanofi-Aventis
- Sanofi-Aventis
- Sanofi-Aventis